According to a recent LinkedIn post from Axtria, the company is promoting an upcoming Ignite webinar focused on the use of generative AI in life sciences and pharma forecasting. The post suggests that traditional forecasting challenges stem from fragmented assumptions across spreadsheets, emails, and meetings, and positions AI as a tool to systematize and enhance this process.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The webinar is set to feature Axtria forecasting head Jeff Olive alongside AstraZeneca’s business planning and capabilities director Eric Haskel, indicating engagement with a major biopharmaceutical player. By highlighting 2026 benchmarking data and practical forecasting constraints, the session appears aimed at decision makers managing small teams and complex stakeholder environments.
For investors, this content points to Axtria’s ongoing push to commercialize AI‑enabled forecasting solutions within the life sciences sector, a segment where more data‑driven planning could support higher‑value analytics contracts. The collaboration with an AstraZeneca executive may also signal deeper relationships with large pharma clients, which could support Axtria’s long‑term revenue visibility and competitive positioning in the pharma analytics and planning market.